YOLFTbeta
30

Tibet Duo Rui Pharmaceutical Co.Ltd.

301075 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

46.26CNY-2.25 (-4.64%)

Price History

Full chart

Market Stats

Previous Close48.51
Open48.30
Day Range45.90 – 49.23
52-Week Range40.08 – 98.29
Volume809.60K
Market Cap5.05B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.61
Dividend Yield0.00%
Beta0.64
50-Day Avg57.16
200-Day Avg65.99

About

Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical formulations, chemical intermediates, and peptide APIs in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as multiple electrolytes injection; sodium acetate ringer's injection. Tibet Duo Rui Pharmaceutical Co., Ltd. was founded in 2005 and is headquartered in Tibet, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Bo Ao
  • Employees461
  • HeadquartersBuilding 1, Tibet, China, China
  • Websitehttps://www.duoruiyy.com

Leadership

  • Mr. Bo AoDeputy GM & Board Secretary · b. 1986

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue449.43M490.16M529.62M401.05M334.30M240.63M154.18M
Growth (%)-+9.06%+8.05%-24.28%-16.64%-28.02%-35.93%
Cost of Revenue23.08M44.39M60.34M92.32M105.13M138.57M141.58M
Gross Profit426.35M445.78M469.28M308.73M229.17M102.06M12.60M
Gross Margin94.86%90.94%88.61%76.98%68.55%42.42%8.17%
Operating Expense342.93M340.75M394.14M292.15M217.22M172.71M107.12M
Operating Income83.42M105.03M75.14M16.58M11.94M-70.65M-94.52M
Operating Margin18.56%21.43%14.19%4.13%3.57%-29.36%-61.30%
EBITDA125.12M143.78M89.26M38.15M44.27M-48.37M-61.11M
EBITDA Margin27.84%29.33%16.85%9.51%13.24%-20.10%-39.63%
Net Income71.71M91.99M68.51M20.50M18.85M-62.67M-102.17M
Net Income Margin15.95%18.77%12.94%5.11%5.64%-26.04%-66.27%
R&D26.65M23.35M24.07M26.45M24.00M37.00M32.41M
R&D as % of Total Revenue5.93%4.76%4.54%6.60%7.18%15.38%21.02%
Interest Expense11.09M1.97M1.18M1.36M3.11M7.90M17.94M
Interest Expense % of Total Revenue2.47%0.40%0.22%0.34%0.93%3.28%11.63%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets294.25M372.97M851.42M898.87M1.07B1.53B1.28B
Total Liabilities144.14M132.25M62.79M145.45M250.59M781.52M659.67M
Total Equity150.37M242.36M792.92M751.53M772.06M676.73M574.51M
Cash95.59M104.49M610.93M425.76M405.27M262.13M85.28M
Net Debt------70.98M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow35.27M63.64M48.15M1.13M12.41M-67.18M-45.83M
Capital Expenditure12.68M50.82M5.35M32.73M23.69M40.92M101.82M
Free Cash Flow22.59M12.82M42.80M-31.60M-11.28M-108.09M-147.65M
Dividends Paid2.14M2.07M1.15M50.84M3.25M17.08M8.79M
FCF to OCF64.05%20.14%88.90%-2804.78%-90.84%160.91%322.15%
Dividend Paid to FCF9.49%16.18%2.69%-160.88%-28.85%-15.80%-5.95%

Earnings

Report DateSep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------
EPS Actual0.150.240.110.060.11-0.02-0.030.210.06-0.01-0.03-0.01-0.17-0.58-0.20-0.34-0.47-0.28-0.180.32
Surprise--------------------
Timing--------------------

Key Statistics & Ratios

Market Cap5.05B
Enterprise Value5.42B
Trailing P/E0.00
Forward P/E0.00
Price / Sales35.28
Price / Book8.03
EPS-0.61
Book Value8.25
Revenue (TTM)143.26M
Gross Profit (TTM)8.98M
EBITDA-46.32M
Profit Margin-33.60%
Operating Margin-27.50%
Return on Equity-9.93%
Return on Assets-4.43%
Shares Outstanding80.00M
Shares Float70.02M
Beta0.64
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
0.13May 31, 2024
20221×
0.63Apr 27, 2022